Zacks Investment Research
31 Jul 2026, 18:20 UTC · 5w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Zacks Equity Research expects Amgen (AMGN) to beat consensus expectations for its second-quarter 2026 earnings report on August 4. — Positive earnings surprises typically drive short-term share price appreciation.
+0.40Amgen is experiencing accelerated sales erosion for Prolia and Xgeva following patent expirations in 2025 and the global launch of biosimilars. — Loss of patent exclusivity and generic competition create long-term structural headwinds for revenue.
-0.30Amgen's growth is being driven by strong volume increases in products such as Repatha, Tezspire, Uplizna, and Evenity. — Strong volume growth in core products offsets losses from legacy patents.
+0.20Continue reading
6 related stories
Top 3 movers · tap to explore
Enbrel and Otezla sales are likely declining due to price reductions in the U.S. and generic erosion in the EU. — Pricing pressure and generic entry erode margins and top-line growth for these specific assets.
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
1d ago
